使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings and welcome to the Align Technology fourth quarter and fiscal year-end 2016 conference call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ms. Shirley Stacy. Thank you, Ms. Stacy. You may begin.
大家好,歡迎參加 Align Technology 2016 年第四季暨會計年度年終電話會議。(接線員指示) 提醒各位,本次會議將被錄音。現在我想把會議交給今天的主持人 Shirley Stacy 女士。謝謝您,Stacy 女士。您可以開始了。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Good afternoon and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO, and John Morici, CFO. We issued fourth quarter 2016 financial results today via Marketwired, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months.
各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同參與電話會議的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。我們今天已透過 Marketwired 發布 2016 年第四季財務結果,相關資訊可在我們網站 investor.aligntech.com 取得。今天的電話會議將以音訊網路直播,並會在我們網站上存檔約 12 個月。
The telephone replay will be available today by approximately 5:30 p.m. Eastern time through 5:30 p.m. Eastern time on February 14. To access the telephone replay, domestic callers should dial 877-660-6853, with conference number 13652166, followed by pound. International callers should dial 201-612-7415 with the same conference number.
電話重播將於今天約美東時間下午 5:30 提供,並持續至 2 月 14 日美東時間下午 5:30。美東時間至美東時間。美東時間於 2 月 14 日。如需收聽電話重播,美國境內來電者請撥打 877-660-6853,會議號碼 13652166,然後按井號。國際來電者請撥打 201-612-7415,會議號碼相同。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the first quarter of 2017 and full year. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more details in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly and Align expressly assumes no obligation to update any forward-looking statements.
提醒各位,今天簡報人員所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2017 年第一季與全年預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容在我們最近向美國證券交易委員會提交的定期報告中有更詳細的說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述的義務。
We have posted historical financial statements, including the corresponding reconciliations and our fourth quarter conference call slides, on the website under quarterly results. Please refer to these files for more detailed information. With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
我們已在網站「季度業績」專區張貼歷史財務報表(包含相對應的調節表)以及第四季電話會議簡報投影片。如需更詳細資訊,請參閱這些檔案。接下來,我將把電話會議交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Thanks, Shirley. Good afternoon and thanks for joining us. On our call today I'll provide some highlights from the quarter and briefly discuss the performance of our two operating segments, clear aligners and scanners. John will provide more detail on our financial results and discuss our outlook for the first quarter and then offer some commentary on how we see 2017 unfolding. Following that, I will come back and summarize a few key points and then we'll open it up to questions.
謝謝你,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將提供本季的一些重點,並簡要說明我們兩個營運部門——透明牙套與掃描器——的表現。John 將更詳細說明我們的財務結果,並討論第一季展望,接著也會就我們如何看待 2017 年的發展提供一些評論。之後我會回來總結幾個關鍵重點,然後開放提問。
Q4 was a strong finish to the year with revenues at the high-end of guidance, up 27.3% year-over-year, resulting from better-than-expected Invisalign and iTero volume, primarily in North America, offset by lowered ASP discounts and FX. Q4 Invisalign case shipments increased 6.9% sequentially, reflecting an uptick in North America and EMEA, and was up 18.5% from the prior year driven by continued growth across all geographies and customer channels. Our iTero business also finished strong, with scanner units up 27.7% sequentially and 171% compared to Q4 a year ago.
第四季為全年畫下強勁句點,營收達到財測區間高端,年增 27.3%,主要來自 Invisalign 與 iTero 出貨量優於預期(以北美為主),但部分被 ASP 折扣降低與匯率影響所抵銷。第四季 Invisalign 病例出貨量季增 6.9%,反映北美與 EMEA 的回升;較去年同期成長 18.5%,動能來自各地區與各客戶通路的持續成長。我們的 iTero 業務同樣強勁收官,掃描器出貨台數季增 27.7%,較去年第四季大增 171%。
EPS was $0.59, which was lower than the outlook, primarily due to an $0.08 impact from exchange rates on a strengthening US dollar that John will explain further in his comments. By all accounts, 2016 was a terrific year for Align. We exceeded $1 billion in annual revenues for the first time in our history. We had more than 700,000 adults and teenagers start orthodontic treatment with Invisalign clear aligners, and we more than tripled our shipments of iTero scanners to nearly 4,000 units, all while delivering several new products, expanding our global footprint and operations, establishing a new doctor direct to consumer channel, the SmileDirectClub, and implementing an entirely new ERP system without any major business disruption.
每股盈餘(EPS)為 0.59 美元,低於展望,主要是因美元走強造成匯率影響 0.08 美元,John 會在後續說明中進一步解釋。各方面來看,2016 年對 Align 而言都是非常出色的一年。我們年度營收史上首次突破 10 億美元。超過 70 萬名成人與青少年開始使用 Invisalign 透明牙套進行矯正治療;iTero 掃描器出貨量更成長逾三倍、接近 4,000 台。同時,我們推出多項新產品、擴大全球版圖與營運、建立新的醫師直達消費者通路 SmileDirectClub,並在未造成重大營運中斷的情況下導入全新的 ERP 系統。
For Q4, North American Invisalign volume was up 5.7% sequentially, driven by expansion of our customer base and increased utilization from both customer channels. During the quarter, North American order flows gained momentum following our Invisalign Summit in November, and North American GP growth was driven by both Invisalign full and express family of products. On a year-over-year basis, the shipment growth of 15.2% was driven by continued adoption by North American orthos, as seen in record utilization and solid growth from GPs, especially with Invisalign Express.
就第四季而言,北美 Invisalign 出貨量季增 5.7%,主要由客戶基礎擴大,以及兩個客戶通路的使用率提升所帶動。本季北美訂單流在 11 月 Invisalign Summit 之後動能增強,而北美一般牙醫(GP)成長則由 Invisalign Full 與 Express 產品家族共同帶動。以年對年來看,出貨量成長 15.2%,主要來自北美矯正專科醫師(ortho)的持續採用(反映在創紀錄的使用率)以及一般牙醫的穩健成長,尤其是 Invisalign Express。
We continue to make progress with the dental service organizations, or what we call DSOs, the fastest-growing segment of the dental industry, which represents nearly 20% of the market today. In Q4, roughly 8% of our North American volume came from DSO practices and they outperformed private practices significantly, both in terms of growth rates and ortho utilization. Q4 Invisalign volume for international doctors was up 9.1% sequentially, driven by strength in EMEA, coming off Q3 summer seasonality, offset somewhat by seasonally slower period in APAC. On a year-over-year basis, international Invisalign volume was up 25%, reflecting continued strong performance across both EMEA and APAC.
我們在牙科服務組織(Dental Service Organizations,簡稱 DSO;我們稱之為 DSOs)方面持續取得進展。DSO 是牙科產業成長最快的區塊,目前約占市場近 20%。第四季,我們北美約 8% 的出貨量來自 DSO 診所;無論在成長率或矯正使用率方面,其表現都顯著優於私人診所。第四季國際醫師的 Invisalign 出貨量季增 9.1%,主要由 EMEA 的強勁表現帶動(承接第三季夏季季節性之後的回升),但部分被 APAC 季節性較慢的期間所抵銷。以年對年來看,國際 Invisalign 出貨量成長 25%,反映 EMEA 與 APAC 皆持續強勁。
In EMEA, Q4 volumes were up 20% year-over-year, reflecting continued adoption of Invisalign in core markets led by the UK, Spain, and France, as well as continued rapid growth in our expansion markets of Central Eastern Europe and the Nordics. We also saw initial momentum with the successful launch of [I Go]. Our Q4 EMEA shipments did not reflect the strong underlying demand, as our reported growth rates were dampened by the imbalance between receipts and shipments that we described in our Q3 earnings call. As our backlog and factory returned to more normalized levels in Q4, there was a dampening effect on the shipments that cut across all regions, because aligners are fabricated and shipped on a first in, first out basis, without regard to geographical region. Notwithstanding this, EMEA still had a record quarter.
在 EMEA,第四季出貨量年增 20%,反映 Invisalign 在核心市場的持續採用(以英國、西班牙與法國領先),以及在中東歐與北歐等擴張市場的持續快速成長。我們也在成功推出 [I Go] 後看到初步動能。我們第四季 EMEA 的出貨量未能反映強勁的基本需求,因為如同我們在第三季法說會所描述,收貨與出貨之間的不平衡壓抑了我們所呈報的成長率。隨著第四季積壓訂單與工廠產能回到較正常水準,出貨量受到抑制的影響橫跨所有地區,因為牙套是依先進先出(FIFO)原則製作與出貨,並不考量地理區域。儘管如此,EMEA 仍創下單季新高。
In Asia-Pacific, Q4 volumes were up 35% year-over-year led by China, Japan, and Southeast Asia. During the quarter, we held numerous clinical education and training events across the region. In China, more than 1,000 doctors attended an Invisalign Day at the China Orthodontic Society's annual meeting. In Japan we held Invisalign Forum, with more than 200 doctors in attendance. And we participated in a Taiwan association of orthodontists' meeting for the first time. We also successfully transitioned from indirect coverage in Korea to direct. The largest beauty cosmetic surgery market in the world is in Korea.
在亞太地區,第四季出貨量年增 35%,由中國、日本與東南亞帶動。本季我們在區域內舉辦多場臨床教育與訓練活動。在中國,超過 1,000 位醫師參加了中華口腔醫學會正畸專業委員會年會的 Invisalign Day。在日本,我們舉辦 Invisalign Forum,出席醫師超過 200 位。我們也首次參與台灣矯正醫師協會的會議。此外,我們也成功將韓國市場由間接覆蓋轉為直營。全球最大的美容整形手術市場位於韓國。
Turning to the teen market, for Q4, the total number of teenagers using Invisalign decreased 7.7% sequentially, as expected, due to the seasonality and was up 19.7% year-over-year, driven by continued adoption worldwide. Q4 is typically a seasonally slower quarter for teenage case starts. For the full-year, 169,000 teenagers started treatment with Invisalign, an increase of 19.6% when compared to last year. The international teen case starts represent about 30% of total case starts and grew 31% in 2016 when compared to last year.
接著談青少年市場:第四季使用 Invisalign 的青少年總數如預期季減 7.7%,主要因季節性因素;但年增 19.7%,反映全球持續採用。第四季通常是青少年病例啟動數較慢的季節性季度。全年共有 169,000 名青少年開始 Invisalign 治療,較去年增加 19.6%。國際市場的青少年病例啟動數約占總病例啟動數的 30%,且 2016 年較去年成長 31%。
Our results reflect solid execution of our strategic growth drivers, which include international expansion, driving ortho utilization of Invisalign, especially among teens; helping GPs treat and refer more cases; and lastly, ensuring that billions of potential patients that we generate through consumer demand programs are offered Invisalign treatment. Product and technology innovation are key to all these initiatives, and in 2016 we continue to see increased clinical confidence as a result of innovation in Invisalign treatment for our customers worldwide.
我們的業績反映出我們在策略性成長驅動因素上的穩健執行,這些因素包括國際擴張、提升 Invisalign 的齒顎矯正(ortho)使用率(尤其是在青少年族群);協助一般牙醫(GP)治療並轉介更多病例;以及最後,確保我們透過消費者需求計畫所帶動的數十億潛在患者,都能獲得 Invisalign 治療的選項。產品與技術創新是所有這些計畫的關鍵,而在 2016 年,我們持續看到因 Invisalign 治療創新而帶來的臨床信心提升,遍及全球客戶。
Q4 is a particularly busy quarter, with product releases designed to improve treatment predictability, outcomes, and efficiency. We launched Invisalign G7 with features that help docs fine-tune certain tooth movements (technical difficulty) key to great outcomes. And we launched the latest version of ClinCheck Pro for more flexibility in treatment planning. We also announced upgrades to our iTero Element scanner software with the Invisalign Outcome Simulator chair-side app, adding 3-D progress tracking to help assess the Invisalign treatment progress. And finally, with the recommendation of many of our most experienced doctors and our North American clinical advisory board, we issued a recommendation for weekly aligner wear in Invisalign full and teen cases, and we are now recommending one week wear for Invisalign Go.
第四季特別繁忙,我們推出多項產品,旨在提升治療可預測性、療效與效率。我們推出 Invisalign G7,其功能可協助醫師微調某些牙齒移動(技術難度)以達成優異療效。我們也推出最新版 ClinCheck Pro,讓治療規劃更具彈性。此外,我們宣布升級 iTero Element 掃描器軟體,加入 Invisalign Outcome Simulator 椅旁應用程式,並新增 3D 進度追蹤,以協助評估 Invisalign 治療進展。最後,在許多最資深醫師及我們北美臨床諮詢委員會的建議下,我們針對 Invisalign 全口與青少年病例提出每週更換牙套的建議;而對於 Invisalign Go,我們目前也建議每週配戴一週更換。
Innovations like our G series features and SmartTrack material give doctors confidence that they can get the results they want with Invisalign while changing aligners weekly instead of every other week. It's a real improvement in treatment efficiency and a better experience for patients to reduce overall treatment time.
像是我們 G 系列功能與 SmartTrack 材料等創新,讓醫師更有信心在每週更換牙套(而非每兩週更換)時,仍能透過 Invisalign 達到想要的結果。這確實提升了治療效率,也因縮短整體療程時間而為患者帶來更佳體驗。
Our integrated consumer marketing program leverages traditionally a media search and digital marketing, PR, and social media to engage consumers at every point in the consumer purchase journey. Consumer interest and demand for Invisalign treatment continues to grow. In 2016, there were over 8 million unique visitors to Invisalign website. 1.8 million potential parents searched an Invisalign provider on Doc Locator, which is up 38% from 2015. And Invisalign's social media community grew 50% to 530,000 consumers.
我們整合式的消費者行銷計畫,傳統上結合媒體搜尋與數位行銷、公關以及社群媒體,在消費者購買旅程的每個接觸點與其互動。消費者對 Invisalign 治療的興趣與需求持續成長。2016 年,Invisalign 網站的獨立訪客超過 800 萬人。有 180 萬名潛在家長透過 Doc Locator 搜尋 Invisalign 供應醫師,較 2015 年成長 38%。而 Invisalign 的社群媒體社群規模成長 50%,達到 53 萬名消費者。
In Q4, our scanner business revenues were up 19.3% sequentially and up 157% year-over-year, reflecting a record number of units shipped in the quarter. Approximately 27.7% quarter over quarter, primarily in North America. Use of the iTero scanners for Invisalign case submissions in place of EVS impressions continues to expand and remains a positive catalyst for Invisalign utilization. For Q4, total Invisalign cases submitted with a digital scanner in North America increased to a record 51.3%, up from 48.8% in Q3 and 39.7% in the same quarter last year. While these scans were predominately from our iTero scanner, we also are seeing some uptick from 3M's True Def and Sirona's Omnicam scanners, which were previously qualified for Invisalign case admissions.
第四季,我們掃描器業務營收較前一季成長 19.3%,較去年同期成長 157%,反映本季出貨台數創下新高。約有 27.7% 的季對季成長,主要來自北美。以 iTero 掃描器取代 EVS 印模來提交 Invisalign 病例的使用持續擴大,並仍是推動 Invisalign 使用率的正向催化因素。第四季,北美以數位掃描器提交的 Invisalign 病例占比提升至創紀錄的 51.3%,高於第三季的 48.8%,也高於去年同期的 39.7%。雖然這些掃描主要來自我們的 iTero 掃描器,但我們也看到 3M 的 True Def 與 Sirona 的 Omnicam 掃描器有所增加;這些掃描器先前已取得 Invisalign 病例受理資格。
Q4 was our first quarter supplying aligners for SmileDirectClub. We continue to work closely with SmileDirectClub teams, developing processes around the manufacture of their aligners and continue to ramp our efforts in referral cases to our network of orthodontists and dentists for in-office Invisalign treatment. The potential of this new -- entirely market -- new market for us is large. While the business is still in its infancy, we remain very excited. I'd like to update you on our plans to expand our operations globally and get closer to our customers' local market.
第四季是我們首次為 SmileDirectClub 供應隱形牙套。我們持續與 SmileDirectClub 團隊密切合作,建立其牙套製造相關流程,並持續加大將轉介病例導入我們的齒顎矯正醫師與牙醫網絡、以進行院內 Invisalign 治療的投入。這個全新——對我們而言完全是新市場——的新市場潛力龐大。雖然業務仍在起步階段,我們依然非常振奮。我想向各位更新我們擴大全球營運、並更貼近客戶在地市場的計畫。
This past July, we transitioned our order acquisition operation, which is the digital scanning of submitted PVS impressions for the EMEA region -- we move into Amsterdam. We focused initially on moving the order acquisition process because of the huge customer experience benefit, which saves several days for initial ClinCheck turnaround time. Order acquisition has a low labor and training component and is therefore relatively easy to relocate. We also get immediate net cost savings for COGS, or cost of goods sold, and a lower freight cost. While it's still early, we're already seeing these benefits from having operations in the region. We're planning to establish order acquisitions for the APAC region in Singapore and expect to begin processing incoming Invisalign cases for that region in early 2018.
去年 7 月,我們將 EMEA 地區的訂單取得(order acquisition)作業——也就是對提交的 PVS 印模進行數位掃描——遷移至阿姆斯特丹。我們最初聚焦於移轉訂單取得流程,因為這能大幅提升客戶體驗,讓初次 ClinCheck 週轉時間縮短數天。訂單取得的勞力與訓練需求較低,因此相對容易搬遷。我們也立即在銷貨成本(COGS,cost of goods sold)以及運輸費用上取得淨成本節省。雖然仍在早期階段,但我們已開始看到在區域內設置營運所帶來的這些效益。我們計畫在新加坡為 APAC 地區建立訂單取得作業,並預期於 2018 年初開始處理該地區的 Invisalign 來案。
Our first treatment planning operations outside of Costa Rica and our first aligner fabrication operations outside of Mexico will both be located in the APAC region. We are focusing on Asia-Pacific first because of the diverse customer needs of that region, language and translational challenges, and the significant distance and time zone differences that currently results in more time for ClinCheck turnaround. The China market will be our initial focus for treatment planning operations in APAC and be located in Chengdu, China. We expect to begin processing Invisalign cases in Q2 2017. A location for our APAC aligner manufacturing has not been finalized yet. However, we plan to be operational in the first half of 2018.
我們在哥斯大黎加以外的第一個治療規劃(treatment planning)營運據點,以及在墨西哥以外的第一個牙套製造(aligner fabrication)營運據點,都將設於 APAC 地區。我們優先聚焦亞太,因為該地區客戶需求多元、語言與翻譯挑戰較大,且目前因距離遙遠與時區差異,導致 ClinCheck 週轉時間較長。在 APAC 的治療規劃營運方面,我們將以中國市場為初期重點,據點設於中國成都。我們預期於 2017 年第二季開始處理 Invisalign 病例。APAC 牙套製造的地點尚未最終確定。不過,我們計畫在 2018 年上半年投入營運。
We plan to establish our operations in EMEA in a similar way. We have treatment planning operations in Cologne, Germany, starting in Q3 2017, followed by Spain in the first quarter of 2018. We are building more detailed plans for putting treatment planning in the other core markets in EMEA over the next few years. International expansion of Invisalign value chain -- which includes order acquisition, treatment planning and aligner fabrication -- is well underway. I'm excited about the opportunity and the potential to get closer to our customers. Our operations are very flexible and we see so many benefits that will allow us to scale with our business and ensure that we offer the best customer support and experience.
我們計畫以類似方式在 EMEA 建立營運。我們將於 2017 年第三季在德國科隆啟動治療規劃營運,接著於 2018 年第一季在西班牙設點。未來幾年,我們正為在 EMEA 其他核心市場導入治療規劃制定更詳細的計畫。Invisalign 價值鏈的國際擴張——包括訂單取得、治療規劃與牙套製造——正穩步推進。我對這項機會以及更貼近客戶的潛力感到振奮。我們的營運非常具彈性,我們看到許多效益,將使我們能隨業務擴張而擴大規模,並確保提供最佳的客戶支援與體驗。
Before I turn the call over to John, I want to update you on our patent litigation. At the conclusion of International Trade Commission action against ClearCorrect in September 2016, we filed a motion in Federal District Court in Houston to lift the stay that had been in place since the filing of the ITC action. The court granted our motion and the matter is now active and we are progressing aggressively, relying in part on those prior findings of infringement and validity from the ITC proceedings.
在我把電話會議交給 John 之前,我想向各位更新我們的專利訴訟進展。在 2016 年 9 月針對 ClearCorrect 的國際貿易委員會(ITC)案件告一段落後,我們在休士頓聯邦地方法院提出動議,要求解除自 ITC 案件提出以來一直存在的中止(stay)。法院准許了我們的動議,案件目前已重新啟動,我們正積極推進,並部分依據 ITC 程序中先前對侵權與有效性的認定。
In addition today, we announced that we have filed a new lawsuit against ClearCorrect and Your Smile Direct LTD of Dublin, Ireland, for patent infringement in the Chancery division of the High Court of Justice in the United Kingdom. We believe that ClearCorrect is now infringing Align's European patent by offering its aligners to consumers through Your Smile Direct and to practitioners through its own distribution through the United Kingdom. The ITC already found Align's US patents to be infringed by ClearCorrect and we will continue to assert and defend our intellectual property rights against the infringement both in the United States and internationally.
此外,我們今天也宣布,已在英國英格蘭及威爾斯高等法院(High Court of Justice)衡平法院庭(Chancery Division)對 ClearCorrect 與位於愛爾蘭都柏林的 Your Smile Direct LTD 提起新的專利侵權訴訟。我們認為 ClearCorrect 目前透過 Your Smile Direct 向消費者提供其牙套,並透過其在英國的自有通路向醫療從業者提供產品,已構成對 Align 歐洲專利的侵害。ITC 先前已認定 Align 的美國專利遭 ClearCorrect 侵害;我們將持續在美國及國際上主張並捍衛我們的智慧財產權,以對抗侵權行為。
With that, I will now turn it over to John Morici. John?
接下來,我把時間交給 John Morici。John?
John Morici - CFO
John Morici - CFO
Thanks, Joe. I'm very pleased to be here. Let's review our fourth quarter financial results. The total Company revenue for the fourth quarter was $293.2 million, up 5.2% from the prior quarter and up 27.3% from the corresponding quarter a year ago. On a constant currency basis, our reported Q4 revenue was reduced by approximately $3 million both sequentially and year-over-year, as a result of foreign exchange rate fluctuation due to the strength of the US dollar.
謝謝,Joe。我很高興能在此。讓我們回顧第四季財務結果。公司第四季總營收為 2.932 億美元,較前一季成長 5.2%,較去年同期成長 27.3%。以固定匯率(constant currency)計算,由於美元走強造成匯率波動,我們第四季報告營收在季對季與年對年兩個比較基準下,均約減少 300 萬美元。
Fourth quarter clear aligner revenue of $251.5 million, which now includes both Invisalign and SmileDirectClub aligner revenue, was up 3.2% sequentially, reflecting growth of Invisalign volume partially offset by lower Invisalign ASPs. Our Q4 shipment volumes and revenue to SmileDirectClub were immaterial to the quarter. Our year-over-year clear aligner revenue growth of 17.5% reflected Invisalign case volume growth across all customer channels and geographies.
第四季透明矯正器營收為2.515億美元,目前已包含Invisalign與SmileDirectClub的矯正器營收,較前一季成長3.2%,反映Invisalign出貨量成長,但部分被Invisalign平均售價(ASP)下降所抵銷。我們第四季對SmileDirectClub的出貨量與營收對本季影響不大。我們透明矯正器營收年增17.5%,反映Invisalign病例量在所有客戶通路與各地區均成長。
Q4 Invisalign ASPs were down sequentially $50 from Q3 to about $1,230, reflecting higher promotional activity and the impact of foreign exchange rates. On a year-over-year basis, Q4 Invisalign ASPs were down approximately $20, primarily due to promotional activity and again the impact of foreign exchange rates, which was partially offset by price increases. For the fourth quarter, total Invisalign shipments of about 190,000 cases were up 6.9% sequentially, reflecting growth primarily from our EMEA and North American customers.
第四季Invisalign ASP較第三季按季下降50美元至約1,230美元,反映促銷活動增加以及外匯匯率影響。以年增角度來看,第四季Invisalign ASP約下降20美元,主要因促銷活動以及同樣的外匯匯率影響,但部分被調價所抵銷。第四季Invisalign總出貨量約19萬例,較前一季成長6.9%,成長主要來自我們的EMEA與北美客戶。
Year-over-year Invisalign case volume growth was 18.5%, driven by growth across all regions. For North American orthodontists, Q4 Invisalign case volume was up 3.2% sequentially and up 20.2% year-over-year. For North American GP dentists, case volume was up 9.1% sequentially and up 9.5% year-over-year. For international doctors, Invisalign case volume was up 9.1% sequentially and up 25% year-over-year, reflecting continued expansion of our customer base as well as increased utilization.
Invisalign病例量年增18.5%,由各區域全面成長所帶動。就北美矯正專科醫師而言,第四季Invisalign病例量較前一季成長3.2%,年增20.2%。就北美一般牙醫(GP)而言,病例量較前一季成長9.1%,年增9.5%。就國際醫師而言,Invisalign病例量較前一季成長9.1%,年增25%,反映我們客戶基礎持續擴張以及使用率提升。
Worldwide Invisalign utilization in Q4 with a record 5.2 cases per doctor, up from 4.9 in Q4 last year. North America ortho utilization was a record 11.3, up from 9.9 in the prior year. North America GP utilization was 3.2, slightly up from 3.1 in the prior year. And international utilization was 5.0, flat from Q4 last year as we continue to expand our customer base. In Q4, we added 3,700 new Invisalign doctors worldwide, of which 1,420 were new North American doctors and 2,280 of which were new international doctors. This compared to 2,615 in Q3 and 2,670 total doctors trained in the same quarter last year. Note that the total number of doctors trained in Q4 includes 670 Invisalign Go doctors in EMEA that were recruited over the course of the year. Our scanner and services revenue for the fourth quarter was $41.7 million, up 19.3% sequentially and up 156.8% year-over-year.
第四季全球Invisalign使用率創新高,每位醫師平均5.2例,高於去年第四季的4.9例。北美矯正專科使用率創新高達11.3,高於前一年的9.9。北美一般牙醫使用率為3.2,較前一年的3.1略增。國際使用率為5.0,與去年第四季持平,因我們持續擴大客戶基礎。第四季我們在全球新增3,700位新的Invisalign醫師,其中北美新增1,420位,國際新增2,280位。相較之下,第三季為2,615位,而去年同期受訓醫師總數為2,670位。請注意,第四季受訓醫師總數包含EMEA地區670位Invisalign Go醫師,這些醫師是在全年期間招募。我們第四季掃描儀與服務營收為4,170萬美元,較前一季成長19.3%,年增156.8%。
Moving on to gross margin. Fourth quarter overall gross margin was 75.1%, flat sequentially and up 0.1 point year-over-year. Clear aligner gross margin for the fourth quarter was 77.5%, down 0.2 points sequentially, primarily due to lower Invisalign ASPs, partially offset by cost leverage from higher volume. Clear aligner gross margins were down 0.4 points year-over-year, primarily due to increased aligners per case as we continue to treat more complex cases. Q4 gross margins for our segment -- our scanner segment was a record 61%, up 3.9 points sequentially and 23.2 points year-over-year. Both the sequential and year-over-year increases were primarily a result of higher ASPs and lower manufacturing costs of our iTero Element scanner relative to our previous scanner.
接著談毛利率。第四季整體毛利率為75.1%,較前一季持平,年增0.1個百分點。第四季透明矯正器毛利率為77.5%,較前一季下降0.2個百分點,主要因Invisalign ASP較低,但部分被較高出貨量帶來的成本槓桿所抵銷。透明矯正器毛利率年減0.4個百分點,主要因每例所需矯正器數量增加,因我們持續治療更複雜的病例。第四季我們掃描儀事業部的毛利率創新高達61%,較前一季上升3.9個百分點,年增23.2個百分點。無論按季或年增的提升,主要來自較高的ASP以及iTero Element掃描儀相較於前一代掃描儀的製造成本較低。
Q4 operating expenses were $151.9 million, up sequentially by $4.8 million or 3.2%, primarily related to increased employee headcount which was partially offset by lower media costs and foreign exchange rate impacts. On a year-over-year basis, Q4 operating expenses were up 33.8%, reflecting increased headcount and continued investment in our go-to-market activities, each critical to the growth of the business. Our fourth quarter operating margin was 23.3%, up 1 point sequentially and down 2.5 points year-over-year. This sequential increase in operating margin relates primarily to OpEx leverage from higher volumes and revenue.
第四季營業費用為1.519億美元,較前一季增加480萬美元或3.2%,主要與員工人數增加相關,但部分被媒體成本下降及外匯匯率影響所抵銷。以年增角度來看,第四季營業費用增加33.8%,反映人力增加以及持續投資於我們的市場進入(go-to-market)活動,兩者皆對業務成長至關重要。第四季營業利益率為23.3%,較前一季上升1個百分點,年減2.5個百分點。營業利益率按季上升主要與較高出貨量與營收帶來的營業費用槓桿有關。
On a year-over-year basis, decreased operating margin primarily reflects higher OpEx as we've grown the business. On a sequential and year-over-year basis, Q4 operating margin was minimally impacted by foreign exchange rate, as we have a natural hedge between our revenue and operating expenses. With regards to our fourth quarter tax provision, our tax rate was 19.8%, up by approximately 1.4 points compared to Q3 of 2016. Recall that Q3 was benefited by a change in our corporate structure as part of our ERP implementation.
以年增角度來看,營業利益率下降主要反映隨著業務成長而增加的營業費用。按季與年增角度,第四季營業利益率受外匯匯率影響極小,因我們在營收與營業費用之間具有自然避險。就第四季所得稅費用而言,我們的有效稅率為19.8%,較2016年第三季約上升1.4個百分點。請回想第三季因ERP導入過程中公司架構調整而受惠。
Commencing in the fourth quarter, we also began supplying aligners to SmileDirectClub. Revenue and costs for this activity are included in our operating profit and reported results, although they were immaterial to the Company. Additionally, we also report our share of SmileDirectClub's losses below operating margin and our tax provision, and is entitled equity and losses of investee, net of tax. This Q4 loss, net of tax, was approximately $1.2 million or $0.01 per diluted share.
自第四季起,我們也開始向SmileDirectClub供應矯正器。此項活動的營收與成本已納入我們的營業利益與對外報告結果中,惟對公司整體影響不大。此外,我們也在營業利益率與所得稅費用之下,列報我們分攤的SmileDirectClub虧損,科目為「被投資公司權益損益(淨額,扣除稅項)」。第四季該項稅後虧損約為120萬美元,或每股稀釋後0.01美元。
Fourth quarter diluted earnings per share was $0.59 compared to $0.63 reported in Q3 and $0.60 reported in the same quarter last year. Fourth quarter EPS was unfavorably impacted by a stronger US dollar, which amounted to approximately $0.08 per share, primarily due to the net realized foreign exchange losses related to the revaluation of certain balance sheet accounts. Addressing unrealized foreign exchange losses included in other income and expense in conjunction with the implementation of our new international corporate structure in July, we changed the functional currency of our Netherlands entity from euro to US dollar.
第四季稀釋後每股盈餘為0.59美元,相較第三季為0.63美元、去年同期為0.60美元。第四季EPS受到美元走強的不利影響,約為每股0.08美元,主要因與部分資產負債表科目重估相關的已實現外匯損失淨額。針對7月導入新的國際公司架構時,其他收益與費用中所包含的未實現外匯損失,我們將荷蘭實體的功能性貨幣由歐元改為美元。
As a result, monetary balance sheet accounts are revalued into US dollars and any impact from that is charged to the P&L. Prior to this change, these impacts were charged to the balance sheet. We have now changed our processes to limit our exposure and the impact of these kinds of currency movements, which we believe should not have nearly as large of an impact on earnings going forward.
因此,貨幣性資產負債表科目會重估為美元,任何影響都會計入損益表(P&L)。在此變更之前,這些影響是計入資產負債表。我們現已調整流程以限制曝險與此類匯率波動的影響,我們相信未來對盈餘的影響不會再如此顯著。
Moving on to the balance sheet. As of the fourth quarter, cash, cash equivalents and marketable securities, including both short and long-term investments, were a record $700 million. This compared to $678.7 million at the end of 2015, an increase of approximately $21.3 million. Of our $700 million of cash, cash equivalents and marketable securities, $241 million was held by the US and $459 million was held by our international entities.
接著談資產負債表。截至第四季,現金、約當現金與有價證券(包含短期與長期投資)創新高達7億美元。相較2015年底的6.787億美元,增加約2,130萬美元。在這7億美元的現金、約當現金與有價證券中,2.41億美元由美國持有,4.59億美元由我們的國際實體持有。
Q4 accounts receivable balance was $247.4 million, up approximately 1% sequentially. Our overall DSO was 76 days, down two days sequentially and up 14 days year-over-year. The year-over-year increase is a result of our new ERP system implemented in July 2016 and other related systems that impacted the timing of our customer collections. As we indicated last quarter, we anticipate that our DSOs will remain above our historical average for several quarters as we work through these changes.
第四季應收帳款餘額為2.474億美元,較前一季約增加1%。整體應收帳款週轉天數(DSO)為76天,較前一季減少2天,年增14天。年增主要源於我們於2016年7月導入的新ERP系統及其他相關系統,影響客戶收款時點。如同我們上季所指出,隨著我們處理這些變更,我們預期DSO在未來數季仍將高於歷史平均水準。
Cash flow from operations for the fourth quarter was $81 million and free cash flow for the quarter -- defined as cash flow from operations, less capital expenditures -- amounted to a record $66.8 million. Capital expenditures for the fourth quarter were $14.2 million, primarily relating to equipment purchases for additional manufacturing capacity as well as building improvements. During the fourth quarter we repurchased approximately 0.4 million shares of stock for $38 million under the April 2014 repurchase plan. Subsequent to year-end we completed this plan, repurchasing the remaining $3.8 million. We still have $300 million available for repurchase under the 2016 repurchase plan which we announced last April.
第四季營運活動現金流為8,100萬美元,而本季自由現金流——定義為營運活動現金流扣除資本支出——達到創紀錄的6,680萬美元。第四季資本支出為1,420萬美元,主要與為增加製造產能而購置設備以及廠房建物改善相關。第四季我們依據2014年4月的庫藏股回購計畫,以3,800萬美元回購約40萬股股票。在年末之後,我們已完成該計畫,回購剩餘的380萬美元額度。在我們於去年4月宣布的2016年回購計畫下,仍有3億美元可用於回購。
Before we move to Q1 outlook, I would like to make a few comments on the full-year 2016 results. In 2016 we shipped a record 708,000 Invisalign cases, up 21.5%. This reflects 32.4% volume growth from our international doctors and 16.4% volume growth from our North American doctors. Shipments of our iTero scanner were up more than three times over 2015 to nearly 4,000 units. Total revenue was a record $1.1 billion, up 27.7% year-over-year. Full-year operating income of $248.9 million, or 23.1% of revenue. Free cash flow was $177.1 million. For the year, we repurchased 1.1 million shares of Align stock for $96.2 million. In 2016 diluted EPS was $2.33.
在我們轉到第一季展望之前,我想先對2016年全年業績做幾點說明。2016年我們出貨創紀錄的708,000件Invisalign病例,成長21.5%。這反映出國際醫師出貨量成長32.4%,以及北美醫師出貨量成長16.4%。我們的iTero掃描儀出貨量較2015年增加逾三倍,接近4,000台。總營收創紀錄達11億美元,年增27.7%。全年營業利益為2.489億美元,占營收23.1%。自由現金流為1.771億美元。全年我們以9,620萬美元回購Align股票110萬股。2016年稀釋後每股盈餘(EPS)為2.33美元。
With that, let's turn to our business outlook and the factors that inform our view. Starting with demand outlook, for our international market expect seasonally slower period for APAC with the Lunar New Year and for EMEA with winter holiday and vacation. For North America seasonally up GP and orthos. For our scanner business, Q1 capital equipment purchases are seasonally slower. With this has a backdrop, we expect the first quarter two shape up as follows.
接下來,我們來看業務展望以及支撐我們觀點的因素。先從需求展望談起,國際市場方面,我們預期亞太(APAC)因農曆新年而呈現季節性較慢;歐洲、中東與非洲(EMEA)則因冬季假期與休假而季節性放緩。北美方面,全科牙醫(GP)與矯正醫師(orthos)季節性上升。掃描儀業務方面,第一季資本設備採購季節性較慢。在此背景下,我們預期第一季將如下發展。
Invisalign case volume is anticipated to be in the range of 200,000 to 203,000 cases, up approximately 22.2% to 24% over the same period a year ago, reflecting continued strong demand across all channels and regions. We expect Q1 net revenues to be in the range of $295 million to $298 million, an increase of 23.6% to 24.8% year-over-year, with gross margins in the range of 74.2% to 74.5%. We expect Q1 operating expenses to be in a range of $162.5 million to $164.5 million, up quarter over quarter primarily due to the increased headcount and increased marketing expenses. Q1 operating margin should be in the range of 19.1% to 19.3%.
Invisalign病例量預計介於200,000至203,000件,較去年同期約成長22.2%至24%,反映各通路與各地區持續強勁的需求。我們預期第一季淨營收介於2.95億至2.98億美元,年增23.6%至24.8%,毛利率介於74.2%至74.5%。我們預期第一季營業費用介於1.625億至1.645億美元,較前一季增加主要因人力增加及行銷費用增加。第一季營業利益率應介於19.1%至19.3%。
Regarding our tax rate, at the start of 2017 we adopted accounting standards update entitled improvements to employee share-based payment accounting. Under this new standard, excess tax benefits and deficiencies associated with employee share-based payments are no longer recognized as paid in capital on the balance sheet, but instead recognized directly to income tax expense or benefit in the income statement for the reporting period in which they occur. Under this new standard, we expect our Q1 effective tax rate to be approximately 1% to 2%, which includes $12 million in excess tax benefit.
關於稅率,2017年初我們採用一項會計準則更新,題為「員工股份基礎給付會計之改進」。依此新準則,與員工股份基礎給付相關的超額稅務利益與不足,不再於資產負債表中認列為繳入資本,而是於其發生之報導期間,直接在損益表中認列為所得稅費用或利益。依此新準則,我們預期第一季有效稅率約為1%至2%,其中包含1,200萬美元的超額稅務利益。
We estimate the Q1 impact of the SmileDirectClub transaction will reduce earnings per share by $0.01 per diluted share, and diluted shares outstanding should be approximately 81.3 million, exclusive of any share repurchases. Taken together, we expect our Q1 diluted earnings per share to be in the range of $0.64 to $0.67, which includes approximately $0.14 of excess tax benefit. Finally, it should be noted that our Q1 CapEx will be larger than normal as we recently entered into a purchase agreement for a new facility in San Jose, California. Accordingly, Q1 CapEx should be approximately $70 million to $75 million.
我們估計SmileDirectClub交易對第一季的影響,將使每股盈餘(按稀釋後每股)減少0.01美元;流通在外稀釋後股數約為8,130萬股,不含任何股票回購。綜合以上,我們預期第一季稀釋後每股盈餘介於0.64至0.67美元,其中包含約0.14美元的超額稅務利益。最後需注意的是,由於我們近期就加州聖荷西(San Jose)一處新設施簽訂購買協議,第一季資本支出將高於正常水準。因此,第一季資本支出約為7,000萬至7,500萬美元。
Now let me turn our view to the full year. We anticipate 2017 revenue growth to be above the midpoint of our long-term operating model range of 15% to 25%. We also expect Invisalign revenue and volume growth to be at or above midpoint of that model. As for our scanner business, recall that 2016 revenue and volume growth significantly benefited from the unfilled backlog carried over from 2015. And while we expect the scanner business to do well and continue to grow, we would not expect the same rate of growth of volume and revenue as we saw in 2016.
現在我把視角轉向全年。我們預期2017年營收成長將高於我們長期營運模型15%至25%區間的中點。我們也預期Invisalign營收與出貨量成長將達到或高於該模型的中點。至於掃描儀業務,請記得2016年的營收與出貨量成長,顯著受惠於2015年結轉的未交付訂單(backlog)。雖然我們預期掃描儀業務表現良好並持續成長,但不預期其出貨量與營收能維持2016年所見的同等成長速度。
We expect operating margins to be flat to slightly up over our 2016 results. Those investments will include geographic expansion, both in countries and markets we already serve as well as expansion into new territories, including Latin America and India; an aggressive direct to consumer advertising campaign targeted directly at teens; international expansion of the Invisalign value chain, including order acquisition and treatment planning to get closer to our customers, as Joe mentioned; commercialization of several new products, including Teen Class II Mandibular Advancement Feature for international markets; Invisalign Go for North America; and new iTero scanner features and functionality; and implementation of the CFM model in North America and APAC, which was previously rolled out in EMEA.
我們預期營業利益率將與2016年結果持平至小幅上升。這些投資將包括:地理擴張——在我們既有服務的國家與市場持續擴張,並拓展至拉丁美洲與印度等新領域;一項積極的直面消費者(DTC)廣告活動,直接鎖定青少年;如Joe所提,擴展Invisalign價值鏈的國際布局,包括訂單取得與治療規劃,以更貼近客戶;多項新產品的商業化,包括面向國際市場的Teen Class II Mandibular Advancement Feature;面向北美的Invisalign Go;以及新的iTero掃描儀功能與特性;並在北美與亞太導入CFM模式(此前已在EMEA推行)。
We believe these investments are key to the continued customer adoption and acceleration of our growth. Similar to last year, many of these investments will take time before they realize meaningful return. We expect the equity loss from our investment in SmileDirectClub to be 2 to 3 times the 2016 losses we recorded. We expect our tax rate for 2017 to be approximately 18%, which includes $19 million of excess tax benefits. Finally, as typical, we expect our earnings power in the second half of the year to be stronger than in the first half, with second half operating profits to account for somewhere in the range of 56% to 58% of our full-year results.
我們相信這些投資是推動客戶持續採用並加速成長的關鍵。與去年類似,這些投資中有許多需要時間才能產生具意義的回報。我們預期對SmileDirectClub投資所產生的權益法損失,將為我們在2016年所認列損失的2至3倍。我們預期2017年稅率約為18%,其中包含1,900萬美元的超額稅務利益。最後,如同以往,我們預期下半年獲利能力將強於上半年,下半年營業利益約占全年結果的56%至58%。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來,我把時間交回Joe做最後的評論。Joe?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Thanks, John. In closing, I'm pleased with our continued progress, but behind all this progress and hard work, what we've really done is to build on the original vision of work started 20 years ago this year, and that is to create a digital way to move teeth with plastic -- predictably, comfortably, and aesthetically. And we're doing that. Digital is the future of orthodontics, which means all teeth in the future will be moved digitally through plastic. We have good momentum and energy heading into 2017, something we all felt at the sales meeting that kicked off the year in North America, APAC and EMEA.
謝謝,John。總結來說,我對我們持續的進展感到滿意;但在所有這些進展與努力背後,我們真正做的是延續並深化20年前於今年啟動的原始願景——也就是以塑膠、用數位化方式來移動牙齒,並且做到可預測、舒適且美觀。而我們正在做到。數位化是齒顎矯正的未來,這意味著未來所有牙齒都將透過塑膠以數位方式移動。我們帶著良好的動能與能量邁入2017年,這是我們在北美、亞太與EMEA的年度銷售會議上都能感受到的。
We have a lot to be excited about, with new products coming to treat younger patients and solutions specifically for general dentists, expanded opportunities through SmileDirectClub, and our new consumer campaigns and much more. I look forward to following up with many of you in the coming weeks at various financial conferences and industrial meetings.
我們有許多令人振奮的事情,包括用於治療更年輕患者的新產品、專為一般牙醫設計的解決方案、透過SmileDirectClub帶來的擴大機會,以及我們新的消費者行銷活動等等。我期待在接下來幾週於各類金融研討會與產業會議上,與各位中的許多人再進一步交流。
Before I open the call to questions, I want to take a minute to welcome Lynn Pendergrass, who will join Align on February 27 in the newly created position of VP, Americas. This newly created position for the Americas region will allow us to provide greater focus on each region, respond to their different needs more quickly and effectively, and harness the collective power of our largest market in the world. We've never had one leader for the region, and with our expansion into Brazil and greater Latin America, we felt it was time to bring all these activities in the Americas under one leader, just as we have in EMEA and APAC regions.
在我開放提問之前,我想花一點時間歡迎 Lynn Pendergrass,她將於 2 月 27 日加入 Align,擔任新設立的美洲區副總裁(VP, Americas)一職。這個為美洲區域新設立的職位,將使我們能夠對各區域提供更聚焦的管理,更快速且更有效地回應不同需求,並整合我們在全球最大市場的集體力量。我們過去從未為該區域設置單一領導者;隨著我們擴展至巴西及更廣泛的拉丁美洲,我們認為是時候將美洲的所有活動整合在同一位領導者之下,就如同我們在 EMEA 與 APAC 區域所做的一樣。
This is an opportunity for us to add an executive with Lynn's experience. Lynn is going to help us scale and continue to grow. I know that she will be an excellent addition to our team. Lastly, as we announced in Q3 earnings, David White will officially leave Align in February. I want to thank David for his many contributions to the Company over the past three years and wish him the best in his retirement.
這對我們而言是一個機會,能夠延攬一位具備 Lynn 這般經驗的高階主管。Lynn 將協助我們擴大規模並持續成長。我相信她會成為我們團隊非常出色的新成員。最後,如同我們在第三季財報中所宣布的,David White 將於 2 月正式離開 Align。我要感謝 David 在過去三年對公司所做的諸多貢獻,並祝福他退休生活一切順利。
With that, we'll now open for any questions you might have. Operator?
接下來,我們現在開放各位提出任何問題。接線員?
Operator
Operator
(Operator Instructions) Robert Jones, Goldman Sachs.
(接線員指示) Robert Jones,Goldman Sachs。
Robert Jones - Analyst
Robert Jones - Analyst
Thanks, Joe, and welcome, John. So, looking at the results, despite what appears to be somewhat of a softening overall dental end market, you guys were able to post and forecast strong case growth. So I guess, Joe, big picture question, how important is overall foot traffic in particular in the GP office relative to how you think about referrals and growth of Invisalign?
謝謝你,Joe,也歡迎你,John。就結果來看,儘管整體牙科終端市場似乎略有走弱,你們仍能公布並預測強勁的案例量成長。所以我想問一個宏觀問題,Joe:在你們看待 Invisalign 的轉介與成長時,整體來客量(尤其是一般牙科診所 GP)相對而言有多重要?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Bob, I think you can never negate foot traffic. It's important that you have store traffic in that sense, that's going to be there. Witness what happened to us in the third quarter. Obviously from a GP market segment we saw that decline. So I think what you are seeing here is the GPs did come back, and kind of from a seasonal standpoint, we expected that as we had indicated in our forecast. But also you see this ortho utilization really picking up in a big way also. So I think it's those combined provide variables. In specific answer to your question, if foot traffic goes down 20% in orthodontics, it's going to affect us in one way or another. But a continuation of 2016 into 2017 is what we are projecting when you hear what John forecasted. And I think that's why we are so bullish in the sense of as we look at 2017.
Bob,我認為你永遠不能忽視來客量。從某種意義上說,門店/診所的來客量很重要,這一定會存在。看看我們第三季發生的情況就知道了。很明顯地,在 GP 這個市場區隔我們看到了下滑。所以我認為你現在看到的是 GP 回來了;從季節性角度來看,我們也如同在預測中所指出的那樣預期會如此。但你也看到矯正科(ortho)的使用率也在大幅提升。所以我認為這兩者結合起來,提供了多個變數。具體回答你的問題:如果矯正科的來客量下降 20%,無論如何都會對我們造成影響。但當你聽到 John 的預測時,我們所預期的是 2016 年的延續並延伸到 2017 年。我想這也是為什麼我們在看待 2017 年時會如此樂觀。
Robert Jones - Analyst
Robert Jones - Analyst
Got it. Just a quick follow-up, you guys called out higher promotional activity as driving the decline in the ASPs. And I know you guys run promotions often, but I don't remember it being this big of a drag on ASPs. Can you maybe just give a little bit more detail on the promotions you ran? And should we expect this level of promotional activity to continue as you think about 2017?
了解。再快速追問一下:你們提到較高的促銷活動導致 ASP 下滑。我知道你們常常做促銷,但我不記得它對 ASP 造成過這麼大的拖累。你能否再多提供一些你們做了哪些促銷的細節?以及在你們看待 2017 年時,是否應預期這種程度的促銷活動會持續?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Yes, I think you know, when you -- look Bob, we have some promotional activity, but I would say nothing would have been out of line with what we've done in the past and fourth quarters. Except there was one 75% bonus -- $75 bonus that we gave to the orthodontic community that came to Las Vegas. And we saw a pretty big uptick from that thing. And so that hit us a little bit from an ASP standpoint but helped volume. But then we had some FX and some mix in here also, so it was a good balance in that sense overall.
是的,我想你知道,當你——Bob,你看,我們確實有一些促銷活動,但我會說,沒有任何一項會超出我們過去在第四季所做的範圍。只是有一個 75% 的獎勵——我們給了前來拉斯維加斯的矯正科社群每人 75 美元的獎金。我們看到那項活動帶來相當大的提升。因此從 ASP 的角度來看,這對我們有一些影響,但有助於帶動量。另外我們也有一些匯率(FX)以及產品組合(mix)的因素,所以整體而言在那個意義上是個不錯的平衡。
Robert Jones - Analyst
Robert Jones - Analyst
Got it. Okay, thanks so much.
了解。好的,非常感謝。
Operator
Operator
Brandon Couillard, Jefferies.
Brandon Couillard,Jefferies。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Joe or John, in terms of the 2017 outlook, first on the top line, can you give us a sense of what you are embedding for FX impact to the top line, as well as the ASP trends for the year? And then as we look in the middle of the P&L you outlined a number of initiatives. Can you help us size or put some numbers to the relative sizes of each of those initiatives, each of the cost buckets, in terms of the incremental commercial spend?
Joe 或 John,關於 2017 年展望,先從營收端來看,你們能否說明你們在營收中納入的匯率(FX)影響假設,以及全年 ASP 的趨勢?接著,從損益表中段來看,你們提到多項計畫。你們能否協助我們量化或提供一些數字,說明各項計畫、各成本項目在增量商業支出上的相對規模?
John Morici - CFO
John Morici - CFO
Yes, I'll take the FX and ASP. We've set our plan for 2017 based on current FX rates, so we've adjusted to what we are currently seeing, and that's what's in our guidance. And as far as ASPs, we expect them to be flat to slightly up as we plan for 2017. From that standpoint. And then from a spend standpoint, we're continuing to invest in our sales and marketing organization and specifically on the marketing on the direct to consumer and really targeting that teen market. So it's a continued investment that we're making in 2017.
好的,我來回答匯率與 ASP。我們是以目前的匯率水準來制定 2017 年計畫,因此我們已調整至我們目前所看到的狀況,而這也反映在我們的財測指引中。至於 ASP,我們預期在規劃 2017 年時,ASP 將持平到小幅上升。就這點而言。而在支出方面,我們將持續投資於銷售與行銷組織,尤其是在面向消費者的直接行銷(direct to consumer),並真正鎖定青少年市場。因此這是我們在 2017 年持續進行的投資。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Brandon, it's Joe. If you think about this from year-to-year, is -- you know what we've done the last few years in this business, is we really did hit the channels hard in the sense of hiring salespeople, feeding the international growth that we have. Just look at our business next year. It's doing exactly the same thing. We are running the same plays, maybe to a higher degree because we have higher momentum and higher volumes to deal with. The real added cost is our teen focus piece for next year. And that will be anywhere between $10 million and $14 million. But I would say that's the inordinate kind of change from year-to-year that we would've had versus our normal kind of OpEx expansion. We feel that's why we struggled so much in the first quarter, in the sense of -- because we load all these investments upfront so we could realize those in the second half of the year.
Brandon,我是 Joe。如果你用年度對年度的角度來看——你知道,我們過去幾年在這個業務上所做的,是在通路端大力投入,例如招募業務人員、支撐我們的國際成長。看看我們明年的業務。做的完全是同樣的事情。我們在執行相同的策略,只是可能程度更高,因為我們要處理更高的動能與更大的量。明年真正新增的成本是我們聚焦青少年的那一塊。那將介於 1,000 萬到 1,400 萬美元之間。但我會說,相較於我們正常的營業費用(OpEx)擴張,這是年度對年度最不尋常的變化。我們認為這也是為什麼我們在第一季會如此吃力——因為我們把這些投資都提前投入,才能在下半年收穫成果。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Thanks. And then curious how you think about the potential risk of a border tax on Mexico imports, and any let's say mitigation efforts that you could take to perhaps offset that? And could you update us on the exact mix of how much of the production is coming out of Mexico today? Is it 100% of the Invisalign volumes?
謝謝。另外也想了解你們如何看待對墨西哥進口課徵邊境稅的潛在風險,以及你們可能採取哪些緩解措施來抵銷其影響?你們能否更新一下目前有多少比例的生產是來自墨西哥?是否 Invisalign 的產量有 100% 都來自那裡?
John Morici - CFO
John Morici - CFO
Out of everything, our production right now is solely in Juarez, Mexico, and 60% of that production goes to North America and 40% goes overseas. Now, you are asking me to comment on Trump's comments. I don't know which tweet you'd want me to address. All those tweets have different financial scenarios in them. Part of this also is going to be a reduction of the corporate tax rate, that looks like it comes together maybe in the 20% range or so. So it's really hard, Brandon, to wash this in and out right now. What I want to give investors confidence that we are aware of it, we'll make the needed kind of changes from a flexibility standpoint.
就所有產品而言,我們目前的生產完全在墨西哥華雷斯(Juarez),其中 60% 的產量供應北美,40% 供應海外。現在,你是在要我評論川普的發言。我不知道你希望我回應哪一則推文。那些推文各自都包含不同的財務情境。其中一部分也可能是公司稅率下調,看起來可能會落在約 20% 左右。所以 Brandon,現在要把這些影響完全釐清進出,真的很難。我想給投資人信心的是:我們已注意到這件事,並會從彈性角度出發,做出必要的調整。
We can be nimble for what needs to be done. But the last thing I'd say is, our Mexican facility, I don't want it to be looked at as a low-cost facility. This is an incredibly high-tech, incredibly important asset to us. And we've invested tons of money over 20 years to bring this as a modern day production facility. It's the biggest 3-D printing business in the world. This is a very valuable asset for us and we'll do all we can just to make that asset as productive as possible regardless of what we see out of the current administration.
我們可以靈活應對需要完成的事情。但我最後想說的是,我們在墨西哥的廠區,我不希望它被視為一個低成本的工廠。這是一項極其高科技、對我們極其重要的資產。而且我們在 20 年間投入了大量資金,把它打造為一座現代化的生產設施。它是全球最大的 3D 列印業務。這對我們而言是一項非常有價值的資產,無論我們從現任政府看到什麼,我們都會盡一切努力讓這項資產盡可能提高生產力。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Fair enough. Thanks a lot.
可以理解。非常感謝。
Operator
Operator
Steve Beuchaw, Morgan Stanley.
Steve Beuchaw,摩根士丹利。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
I wonder if we could reflect just for a minute on the first quarter guidance. When I think back to the Company's approach to guidance over the years, there's been a -- there have been times where we thought, wow, the guidance could have been a little higher, but the Company has pretty steadfastly stuck to this view of looking at past sequential trends, seasonal trends to say, okay, here is where we think the business is going to grow. When I look at the first quarter, though, the guidance for the sequential volume growth significant relative to trend, stronger than normal trend. So I wonder if you could spend just a minute there cluing us in to anything we might be missing about what might be different this time around.
我想我們能否花一點時間回顧一下第一季的指引。回想公司多年來對指引的做法,曾經有些時候我們會覺得,哇,指引本來可以再高一點,但公司一直相當堅定地採取這種觀點:看過去的連續趨勢、季節性趨勢,然後說,好,這就是我們認為業務將如何成長。但我看第一季時,對於連續出貨量成長的指引,相較於趨勢顯著偏強,強於正常趨勢。所以我想請你們花一點時間提示我們一下:這次有什麼不同,或我們可能漏掉了什麼?
John Morici - CFO
John Morici - CFO
Steve, this is John. I think what we saw, we saw very good volume in Q4. And I think that is what led to strong shipments and strong revenue performance in Q4, and we've seen that continue into January and into 2017. So we feel very good about where we are at from a volume standpoint, and that's why we've given the Q1 guidance and it helps strengthen where we think we are going to be at for 2017.
Steve,我是 John。我想我們在第四季看到非常好的出貨量。我認為這帶動了第四季強勁的出貨與營收表現,而我們也看到這股趨勢延續到一月以及 2017 年。所以從出貨量的角度來看,我們對目前的位置感到非常有信心,這也是我們給出第一季指引的原因,並且有助於強化我們對 2017 年的看法。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
As you look back at order patterns over the last several months, do you think it might have been in part more of a timing issue, where new orders were delayed out to the latter stages of the year and into January?
回頭看過去幾個月的訂單型態,你們是否認為其中一部分可能是時點問題,也就是新訂單延後到年底後段以及一月?
John Morici - CFO
John Morici - CFO
I think you've got to look at Q4-Q1 normal lift, too, on this, Steve. There is some seasonality in this. That's how we go about things, too. So I hope we are answering your question, but I know what you are saying is that we are probably a little outside of what kind of guidance we've given in the past. I'd just take John's comments in the sense of momentum but also your understanding of the seasonality of this business Q4 to Q1 is the two main variables of why we're predicting Q1 to be what it is.
Steve,我覺得你也得把第四季到第一季的正常拉升納入考量。這裡面確實有一些季節性。我們做事的方式也是如此。所以我希望我們有回答到你的問題;但我知道你的意思是,我們這次的指引可能比過去給的範圍稍微更偏離一些。我會把 John 的評論理解為動能,再加上你對這個業務第四季到第一季季節性的理解,這兩個主要變數就是我們為何預測第一季會是這樣的原因。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Yes. Just to pile on, Steve, just because I'm -- you might recall if you -- the order imbalance that we referenced on the Q3 call that -- keep in mind, right, that strength carried over. Receipt -- restraint, which is receipt strength, obviously carried over as the inventory and backlog evened out in Q4. And that strength obviously has carried over into Q1.
是的。再補充一下,Steve,因為我——你可能還記得我們在第三季電話會議上提到的訂單不平衡——請記住,對吧,那股強勢延續了下來。收單——抑制,亦即收單強勁,顯然在第四季庫存與積壓訂單趨於平衡時延續了下來。而那股強勢顯然也延續到了第一季。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Got it. Last one from me is actually (multiple speakers)
了解。我最後一個問題其實是(多位發言者)
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
This was actually -- Steve, I think you even said something about this on the last earnings call. You asked whether this would carry over into Q1, and that's potentially what you are seeing.
其實這個——Steve,我想你甚至在上次財報電話會議上也提到過。你問過這是否會延續到第一季,而你現在看到的可能就是這件事。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Well, don't give me too much credit, Shirley.
嗯,別給我太多功勞,Shirley。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
(multiple speakers) We won't give you credit for the strength, but --
(多位發言者)我們不會把強勁表現的功勞算在你頭上,但——
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Last one for me. I wonder if you could give us in the early reflections on the traction you're getting with the one-week change out. How broadly are you seeing that adopted if it's something you can pick up from your friends in the channel? And what is the early feedback? Are clinicians thinking about this as in any way changing the way they go about using Invisalign? Thank you.
我最後一個問題。我想請你們談談對「一週更換」方案目前獲得的初步反饋與進展。如果你們能從通路夥伴那邊掌握到的話,這項做法的採用範圍有多廣?以及早期回饋是什麼?臨床醫師是否認為這會在某種程度上改變他們使用 Invisalign 的方式?謝謝。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Yes. I think we've had good reception from a doctor standpoint of it, Steve. And the data that we presented, the clinical evidence as far as why this works -- you know, SmartTrack, SmartForce; the innate aspects of our product line that allows us to have it. I honestly feel some of the doctors are aggressively pursuing this, and the ones who are really investing in Invisalign in a big way has a significant share of share. Other ones are more cautious, I think, in the sense of how they start up, and that's just part of the tendency of this industry.
是的。Steve,我認為從醫師端來看,我們獲得了不錯的反響。而我們所呈現的數據、臨床證據,關於為什麼這樣可行——你知道的,SmartTrack、SmartForce;以及我們產品線內建的特性,使我們能做到這點。老實說,我覺得有些醫師正在積極推動這件事,而那些在 Invisalign 上投入很大的醫師,市占份額也相當可觀。另外一些則比較謹慎,我想是在他們如何開始導入的層面上,而這也只是這個產業的一種傾向。
The last thing I would say is it's going to be really important for us as part of our communications to patients is the availability of this kind of opportunity. I think as patients ask for that as they move into orthodontists or the GP for treatment, that just see more and more enthusiasm and uptake of that all.
我最後想說的是,作為我們對病患溝通的一部分,讓病患知道有這類機會可用,將會非常重要。我認為當病患在進入矯正專科醫師或一般牙醫(GP)接受治療時提出這樣的需求,我們就會看到越來越多的熱情與採用。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Got it. Really appreciate the help.
了解。非常感謝你們的協助。
Operator
Operator
John Kreger, William Blair.
John Kreger,William Blair。
John Kreger - Analyst
John Kreger - Analyst
Joe, I believe in your prepared remarks you talked about the Invisalign order backlog generally coming back to normal. Can you just expand upon that? Is there any imbalance in the backlog that still persists in the first quarter or are you totally back to normal there?
Joe,我記得你在事先準備的發言中提到,Invisalign 的訂單積壓大致已回到正常水準。你能否再多說明一下?第一季是否仍有任何積壓結構上的不平衡,還是已經完全恢復正常?
John Morici - CFO
John Morici - CFO
We are back to normal, John.
John,我們已經回到正常了。
John Kreger - Analyst
John Kreger - Analyst
Great, great. And then John, the 2017 outlook commentary that you gave, which was very helpful, can you give a sense about what the SmileDirectClub contribution would likely be, based upon your expectations to either revenue or volumes?
很好,很好。接著 John,你對 2017 年展望的評論非常有幫助;你能否就 SmileDirectClub 的貢獻提供一些概念?依你們的預期,它對營收或出貨量大概會是什麼程度?
John Morici - CFO
John Morici - CFO
Yes sure, John. It's very minimal. We are definitely ramping up and growing with SmileDirectClub, but in our numbers it's very, very minimal.
好的,當然可以,John。非常小。我們確實正在與 SmileDirectClub 加速導入並成長,但在我們的數字裡,它非常、非常小。
John Kreger - Analyst
John Kreger - Analyst
Great, thanks. Just one last one. Joe, you mentioned that DSOs are becoming a much bigger part. Are you seeing that globally or really just in the US? And how do you think about that from a mix impact on your business either in terms of ASP or margins? Thanks.
很好,謝謝。最後一個問題。Joe,你提到 DSO 正在成為更大的一部分。你們看到的是全球性的現象,還是主要在美國?以及就你們業務的組合影響而言,你們如何看待它對 ASP 或毛利率的影響?謝謝。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
John, that's a good question. First of all, this is more of a US kind of phenomenon. That's not to say that other heavy GP markets, like the UK or whatever, won't go through this consolidation effect. Obviously there is some -- just a large DSOs out there that, from a deal standpoint, we obviously incentivize to drive volume. But right now we are not looking at any kind of I'd say material effect in the sense of ASP. Because we -- balances on other full cases and things that we offer. So, as we go forward we'll be continuing to report as to how we are working with DSOs and how things are going. But as you prepare like a model, John, for 2017 I wouldn't think that you want to handicap it for DSO price [mix]. Okay?
John,這是個好問題。首先,這比較像是美國的現象。但這不代表其他以一般牙醫(GP)為主的市場,例如英國之類,不會經歷這種整併效應。顯然外面有一些——一些大型 DSO,從交易條件的角度來看,我們確實會提供激勵以帶動出貨量。但就目前而言,我們並未看到我會說是對 ASP 造成任何實質影響。因為我們——在其他完整病例以及我們提供的其他項目上有做平衡。因此,隨著我們往前走,我們會持續回報我們如何與 DSO 合作以及進展如何。但 John,如果你在為 2017 年建立模型,我不會認為你需要把 DSO 的價格[組合]因素納入折扣或調整。好嗎?
John Kreger - Analyst
John Kreger - Analyst
Great, great. Thank you.
很好,很好。謝謝。
Operator
Operator
Rich Newitter, Leerink Partners.
Rich Newitter,Leerink Partners。
Ravi Misra - Analyst
Ravi Misra - Analyst
This is actually Ravi in for Rich. One question on the gross margin. Just a little bit curious. It came in -- guidance for 1Q was a little bit lighter than we had thought, given that your case volume guidance was a little bit higher. I'm just wondering if you could explain the puts and takes around that (technical difficulty). I had a follow-up.
其實我是代替 Rich 的 Ravi。有一個關於毛利率的問題。只是有點好奇。你們對第一季的指引——比我們原先想的稍微保守一些,因為你們的病例量(case volume)指引反而稍微高一些。我想請問你們能否解釋一下其中的增減因素(technical difficulty)。我還有一個追問。
John Morici - CFO
John Morici - CFO
From a gross margin standpoint we are going to continue to see some FX pressure. ASP is what we expect in the first quarter to be a little bit better than the first quarter due to some of the promotional activity that won't continue from Q4 into Q1. And I think it's -- we haven't -- from a standpoint of planning our pricing for 2017, in the past we've taken is price increases in the past couple of years. We haven't planned that for 2017 yet, so that might be something that is further down.
就毛利率而言,我們將持續看到一些匯率(FX)壓力。ASP(平均銷售價格)方面,我們預期第一季會比第一季稍微好一些,因為第四季的一些促銷活動不會延續到第一季。另外我想——我們尚未——從規劃 2017 年定價的角度來看,過去幾年我們都有做過漲價。我們目前還沒有把 2017 年的漲價納入規劃,所以這可能會是之後才會考慮的事情。
Ravi Misra - Analyst
Ravi Misra - Analyst
Great, thanks. Then one on just maybe the portion of your revenue mix. The scanner business, you had the new launch sort of hitting its [full] stride last year. It's growing pretty impressively. It seems that we should be expecting that this year. In 2017 should we still think of the scanner business as growing faster than the clear aligner business? What commentary can you provide on the backlog? Thanks.
很好,謝謝。接著想問一下你們營收組合的部分。掃描器業務方面,你們的新產品上市在去年似乎已經進入[全面]發力的階段。成長相當亮眼。看起來今年我們也應該會期待同樣的趨勢。在 2017 年,我們是否仍應該把掃描器業務視為比隱形矯正器業務成長更快?你們對積壓訂單(backlog)有什麼評論可以分享?謝謝。
John Morici - CFO
John Morici - CFO
Yes, definitely we had a great backlog come in out of 2015 into 2016 for iTero, and that's contributed to the significant growth. The backlog is much more normalized for an equipment business now for iTero. So for 2017, we expect consistent growth to maybe a little bit better than Invisalign, but certainly nothing like we saw in 2016 because of the backlog.
是的,確實如此。我們在 2015 年到 2016 年之間,iTero 帶來了非常好的積壓訂單,這也促成了顯著的成長。目前 iTero 的積壓訂單已經更趨於設備業務的正常水準。因此在 2017 年,我們預期會有穩健成長,可能會比 Invisalign 稍微好一些,但肯定不會像 2016 年那樣,因為當時有積壓訂單的因素。
Ravi Misra - Analyst
Ravi Misra - Analyst
(multiple speakers) That was it for me, thanks.
(多位講者) 我這邊就這些了,謝謝。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Operator, next question.
接線生,下一個問題。
Operator
Operator
Jon Block, Stifel.
Jon Block,Stifel。
Jon Block - Analyst
Jon Block - Analyst
Joe, you gave 2017 guidance, so maybe now I could ask about 2018 and beyond. But a better top line for 2017 but also higher spend, so it looks like you are getting to a similar operating income. Or absolute dollars not far off from where we were, but just a different formula getting there, and in and around that 23% op margin. Just taking a step back, when you look out where the business is today from an investment standpoint, where do we start to see that elusive leverage? You've got tremendous top line, and it really is huge, but you are still sort good couple hundred basis points below the low-end of that 25% to 30% EBIT goal. So maybe can you speak to -- when you look out beyond 2017, how you bring the leverage back to the business?
Joe,你已經給了 2017 年的指引,所以也許我現在可以問 2018 年以及更長期的情況。2017 年營收端更好,但支出也更高,所以看起來你們的營業利益會落在相近水準。也就是說,絕對金額跟我們之前看到的差不多,但達成的方式不同,且大致落在 23% 的營業利益率附近。退一步來看,從投資角度看目前的業務狀態,我們何時會開始看到那個一直很難出現的營運槓桿?你們的營收成長非常強勁,規模也很大,但你們仍比 25% 到 30% 的 EBIT 目標區間下緣低了大概幾百個基點。所以也許你能談談——展望 2017 年之後,你們要如何把槓桿帶回到這個業務上?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
When you say bring leverage back, Jon, I hope that we've been leveraging. We just haven't been to the point of the 25% or 30% that everyone here wants to get to and what you guys look for. I'd say, Jon, what we are constantly faced here with are actually really great short-term investments for us to expand this business significantly and an operating expense that's almost immediately accretive within that year. And so, I think at some point in time, as we become more and more penetrated or over-utilization of these markets, more spread internationally in a sense -- when we go internationally, you just don't higher salespeople. You have to put infrastructure in place. You have legal functions. There's a lot of things you have to put in place to put this organization together.
Jon,你說把槓桿帶回來,我希望我們其實一直在做槓桿化。只是我們還沒到大家都希望、你們也期待的 25% 或 30% 水準。我會說,Jon,我們在這裡一直面臨的是:有一些對我們而言非常好的短期投資機會,可以大幅擴張這個業務,而這些營業費用幾乎在當年就能立刻帶來增益(accretive)。所以我想在某個時間點,當我們在這些市場的滲透率越來越高,或是使用率更充分,並且在國際市場更廣泛鋪開——從某種意義上說,當我們走向國際化時,你不只是多聘業務人員而已。你必須建立基礎設施。你需要法務職能。你需要建立很多東西,才能把這個組織搭建起來。
So, I can't tell you that -- I don't want to start forecasting 2018, 2019 or whatever, Jon, but I hope what you see here is an incredibly profitable business that throws out a ton of cash year in and year out. We are in the 23%. We are in striking distance of the 25% range. If we wanted to cut back some of that investment and sacrifice some growth, we could be at 27% tomorrow. We just feel like it's the right thing for this business to do to keep investing in these -- what I would say accretive types of investments to payback within a year to 18 months. And you are seeing it in our results, you are seeing it in the growth, and that's our outlook right now.
所以,Jon,我不能跟你說——我不想開始預測 2018、2019 或其他年份,但我希望你看到的是:這是一個極度獲利的業務,每年都能產生大量現金。我們目前在 23%。距離 25% 的區間已經很接近。如果我們想要縮減部分投資、犧牲一些成長,我們明天就可以到 27%。但我們認為,對這個業務而言,持續投資在這些——我會稱之為具增益性的投資——而且能在 12 到 18 個月內回收,是正確的做法。你們也在我們的結果中看到了、在成長中看到了,這就是我們目前的展望。
But as we go forward I'm very confident we are going to reach the 25% to 30% range. It's just we'll continue to invest to grow and improve that utilization rate where it makes sense for the business.
但往前看,我非常有信心我們會達到 25% 到 30% 的區間。只是我們會持續投資以推動成長,並在對業務合理的地方提升使用率。
Jon Block - Analyst
Jon Block - Analyst
Got it. No, very helpful and fair enough. A second one, unless I missed the EMEA commentary, it seemed like it suggested that trends picked up throughout the quarter. So 4Q orders were higher than shipments, and arguably that sets up well for 1Q 2017 shipments. I believe [I Go] was launched in the quarter in the UK and Germany during that fourth quarter. So any thoughts on the early traction or findings from I-Go in EMEA? And when do you expect I Go to be released here in North America? Thanks, guys.
了解。不,這很有幫助,也很合理。第二個問題,除非我漏聽了你們對 EMEA 的評論,你們似乎暗示整個季度的趨勢是逐步改善的。所以第四季的訂單高於出貨,某種程度上這對 2017 年第一季的出貨是個不錯的鋪墊。我相信 [I Go] 在該季度於英國與德國在第四季推出。所以對於 I-Go 在 EMEA 的早期採用情況或初步觀察,有什麼想法嗎?另外,你們預期 I Go 何時會在北美推出?謝謝各位。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
As far as I Go uptake, we saw good uptake in the UK. We're working through Germany. Germany usually has a slower infusion rate than most countries in the sense of how they go about things. We're moving into Australia in that sense and bringing it over to APAC. And we will introduce it -- we are beginning to introduce it here in certain regions in the United States. So we'll keep you updated, Jon. We are excited about that product. We do need something for that GP segment that's simple, that allows GPs to assimilate this product quickly and see how it integrates into their workflow. So you'll see us aggressively push that product around the globe and in North America as we move into 2017.
就 I Go 的採用情況而言,我們在英國看到不錯的採用。我們正在推進德國市場。德國通常在導入速度上比多數國家更慢一些,因為他們做事的方式就是如此。我們也正往澳洲推進,並把它帶到亞太(APAC)。同時我們也會在美國的某些地區開始導入——我們已經開始在這裡的特定區域推出。所以我們會持續向你更新,Jon。我們對這個產品感到興奮。我們確實需要一個針對一般牙醫(GP)族群、簡單易用的產品,讓 GP 能快速上手並了解它如何整合進他們的工作流程。因此你會看到我們在 2017 年推進過程中,積極在全球以及北美推廣這個產品。
Jon Block - Analyst
Jon Block - Analyst
All right, perfect. Thanks, guys.
好,完美。謝謝各位。
Operator
Operator
Jeff Johnson, Robert W. Baird.
Jeff Johnson,Robert W. Baird。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Joe, let me follow up on Jon's margin questions. And you might not have liked his question. You'll probably like mine even less, I guess. But I'm just trying to understand; operating margin has been down a couple hundred basis points this quarter. It seems like you are guiding down 250 basis points or so next quarter and yet guiding flat for the year. And I really respect a lot of the investments you are making. I think they are the right calls for the business in 2017 and beyond. So just trying to understand if the last couple quarters, or at least 4Q and 1Q are down, how do we get flat for all of 2017 in the face of some of these investments that you are making?
Joe,我想延續 Jon 關於毛利率的問題追問一下。你可能不太喜歡他的問題。我猜你可能更不喜歡我的問題。但我只是想理解:本季營業利益率下滑了幾百個基點。看起來你們對下季的指引又下調了大約 250 個基點,但對全年卻指引持平。我非常尊重你們正在做的許多投資。我認為這些對 2017 年及更長期的業務都是正確的決策。所以我只是想理解:如果最近幾季,至少第四季和第一季是下滑的,在你們進行這些投資的情況下,我們要如何在 2017 年全年做到持平?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Jeff, I think I've been here long enough to be through a few of these first quarters now. I think you know that our first quarter a lot of stuff hits; depresses operating margin in the sense of salaries and how we account for things. We lay in investments for the rest of the year, so it's always our most pressured quarter from an operating profit standpoint. So, look at that comparison from 4Q to 1Q. That's always a tough comparison in the sense of how the business operates. I'll step back. Jeff, I don't mind Jon's question. I think it's a question that we always ask ourselves here, so I never want you guys to misinterpret that we would get upset over a question like that. I think it's legitimate and it's something that we wrestle with here.
Jeff,我想我在這裡待得夠久了,已經經歷過幾次這樣的第一季了。我想你也知道,我們第一季會有很多項目入帳;就薪資以及我們如何進行會計處理而言,會壓低營業利益率。我們會為全年其餘時間先行投入投資,所以從營業獲利的角度來看,第一季一向是我們壓力最大的季度。所以,看看從第四季到第一季的那個比較。就業務運作方式而言,這一直都是個艱難的比較。我先退一步說。Jeff,我不介意Jon的問題。我覺得這是我們在這裡一直會問自己的問題,所以我不希望你們誤解,以為我們會因為這樣的問題而不高興。我認為這是合理的,而且也是我們在這裡會反覆思考、努力拿捏的事情。
As we forecast for next year, you are right. We are keeping -- our projections for operating profit are pretty much flat with what we were this year. We see our growth as pretty phenomenal in the sense of what we're forecasting. We think that's the right focus for this business right now. Look, I'd just say from a speculative standpoint, if I came and told you we're going to be 18% operating profit for all of next year because we're doing something, I would say that would probably be out of the realm of what you'll see from this team. But we want to be as close to the edge as we possibly can in making sure we produce good margin and cash for this business and take advantage of all the opportunities we have to [grow with them]. That's a balance that we hope we are communicating to you and that we are executing on.
在我們對明年的預測上,你說得沒錯。我們維持——我們對營業利益的預測大致與今年持平。就我們所預測的內容而言,我們看到的成長相當驚人。我們認為這正是目前這門業務應該聚焦的重點。你看,我只是從推測的角度說,如果我跑來告訴你,因為我們在做某些事,明年全年我們要做到18%的營業利益率,我會說那大概不會是你們從這個團隊看到的情況。但我們希望在確保為這門業務帶來良好的利潤率與現金、並把握所有機會去[與他們一起成長]這件事上,盡可能貼近極限。這是一種平衡,我們希望已經向你們傳達清楚,也希望我們正在把它落實執行。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
That's helpful. And then last question, I guess -- well, two. One for John. Can you remind me, John, does the peso weakness that we've seen so much and accelerate here recently, does that help at all from a margin perspective? I think the answer is yes, but just if you could remind me there. And then on the ASPs, I know the question has been asked a couple of times, Joe, but just want to circle back there. They have been declining here over the last couple of years and I know the promotional activity and some of the utilization rates, people are hitting their targets, things like that, so that's all good. But I think you said DSO is flat on the year and that would definitely be a change in the trend line from the last couple years. So just want to confirm maybe what's driving the flattening out of those ASPs after a couple of years of having come down a bit.
這很有幫助。然後最後一個問題,我想——嗯,其實兩個。一個問John。John,你能提醒我一下嗎?我們看到披索走弱,而且最近加速走弱,這在利潤率角度上是否有任何幫助?我想答案是有,但想請你再提醒我一下。另外關於ASP,我知道這個問題Joe已經被問了幾次,但我想再回到這點。過去幾年它們一直在下降,我知道促銷活動以及一些使用率,人們達到他們的目標之類的,所以這些都很好。但我想你說DSO今年持平,這肯定會改變過去幾年的趨勢線。所以想確認一下,在經過幾年略有下滑之後,是什麼在推動這些ASP趨於持平。
John Morici - CFO
John Morici - CFO
Jeff, to answer your question on peso, yes, the dollar strengthening against the peso is favorable for us because of the costs there.
Jeff,回答你關於披索的問題,是的,美元相對披索走強對我們有利,因為那邊的成本。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
On your DSO question, I'd say don't misinterpret my answer on DSO -- the DSOs, we may have some pretty good targets in the sense that they can grow. They will get a commensurate kind of a discount from an Invisalign standpoint. What I'm saying is in the whole mix of products that we have in North America, don't over-weigh that thing as pulling down the overall total. But you'll see if DSOs can grow aggressively, they will be rewarded for it, and I think that we'll continue to go that way.
關於你的DSO問題,我會說不要誤解我對DSO的回答——DSO方面,我們可能有一些相當不錯的目標,從它們能夠成長的角度來看。它們會在Invisalign方面獲得相應的折扣。我想說的是,在我們北美整體產品組合中,不要過度把這件事視為拉低整體總額的主要因素。但你會看到,如果DSO能夠積極成長,他們會因此得到回饋,我想我們會持續朝這個方向走。
From an ASP standpoint, I think -- you have to remember we got price last year, too. And that helps in that sense. FX didn't help us in the fourth quarter in that way also. So, we're playing in a bandwidth here of price increases, FX of $20 or so, and I have no idea what -- do you know what that is, Shirley?
從ASP的角度來看,我想——你必須記得我們去年也有調價。這在那個意義上是有幫助的。匯率在第四季也沒有在這方面幫到我們。所以,我們是在一個區間內運作:包含漲價、約20美元左右的匯率影響,而我也不知道——Shirley,你知道那是什麼嗎?
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
(laughter) International mix is growing faster.
(笑聲)國際組合成長更快。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Yes. Oh yes, international mix, which is (multiple speakers)
是的。喔是的,國際組合,這是(多位講者)
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
For full cases, higher ASPs outside the United States, especially APAC.
就完整病例而言,美國以外的ASP更高,尤其是亞太地區。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Yes. Look, I think David continued to guide ASPs that were pretty much a constant from year-to-year. We still think about that, but there is a lot of noise in that when you think of FX and promotions that we do and mix, like Shirley mentioned. But we are counting on it pretty level as we go into 2017.
是的。你看,我想David持續指引ASP基本上會年對年維持不變。我們仍然這樣看待,但當你考慮匯率、我們做的促銷,以及像Shirley提到的產品組合時,裡面會有很多雜訊。但我們在進入2017年時,預期它會相當平穩。
Jeff Johnson - Analyst
Jeff Johnson - Analyst
Fair enough. Thanks, guys.
可以理解。謝謝各位。
Operator
Operator
Steven Valiquette, Bank of America Merrill Lynch.
Steven Valiquette,美國銀行美林。
Steven Valiquette - Analyst
Steven Valiquette - Analyst
Congrats on the results. Just for us, a couple quick questions here, just on the litigation news that was in the other press release today. Just first on that patent lawsuit news in the UK, we don't have as much background on UK market dynamics. I guess I'm just wondering if you're able to provide any current approximate market share splits maybe for you and others, such as ClearCorrect, in that market. Then I have a follow-up after that.
恭喜這次的業績。我們這邊有幾個簡短問題,關於今天另一份新聞稿中的訴訟消息。首先是英國那起專利訴訟的消息,我們對英國市場動態沒有那麼多背景。我想請問你們是否能提供目前大概的市占率分布,例如你們與其他業者(如ClearCorrect)在該市場的占比。之後我還有一個追問。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
As far as -- I can't give you any real -- but it's not material in the sense of ClearCorrect's market share in the UK. And this is -- this entity over in the UK, I want to be sure everyone knows, sounds like SmileDirectClub, but it's not. It's nothing to do with it. And so, pretty much what ClearCorrect did here was try to continue with a model that they had with SDC and to hook up with someone in the UK that really wants to try to implement a similar model. And so, obviously our lawsuit is designed exactly with what we did with ClearCorrect, but it extended, as we mentioned, to an international market. And we'll continue to be aggressive in defending our IP.
就——我無法給你任何確切的——但就ClearCorrect在英國的市占率而言,並不具重大性。另外我想確保大家都知道,英國那邊這個實體聽起來像SmileDirectClub,但其實不是。跟它完全無關。所以,ClearCorrect在這裡做的,基本上是試圖延續他們與SDC合作時的那種模式,並與英國某個很想嘗試導入類似模式的對象合作。因此,很明顯我們的訴訟設計與我們對ClearCorrect所做的完全一致,只是如我們提到的,延伸到了國際市場。我們會持續積極捍衛我們的智慧財產權。
Steven Valiquette - Analyst
Steven Valiquette - Analyst
Okay. And then as far as the implications, then, of refiling the action in the federal court in Houston, again without having the full historical background at my fingertips, is this still related more to the patents that are set to expire this year in the US? Or is it more geared towards US patents that go well beyond this year?
好的。那就其影響而言,在休士頓聯邦法院重新提起訴訟——同樣地,我手邊沒有完整的歷史背景——這是否仍主要與美國今年即將到期的那些專利有關?還是更偏向於那些有效期遠超過今年的美國專利?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
We've got a special guest star here today. Roger can help me out through this, okay?
我們今天有位特別來賓。Roger可以幫我回答這個,好嗎?
Roger George - VP, Legal Affairs and General Counsel
Roger George - VP, Legal Affairs and General Counsel
Good afternoon, everybody. The patents that are before the court in the ClearCorrect action are a combination of patents that will expire in the next couple of years and also patents with a longer lifespan.
各位下午好。在ClearCorrect案件中提交法院審理的專利,包含一部分將在未來幾年內到期的專利,也包含一部分存續期更長的專利。
Steven Valiquette - Analyst
Steven Valiquette - Analyst
Okay. But as far as the (multiple speakers) -- go ahead.
好的。但就(多位講者)——請繼續。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
I think we already explained that they are still liable for those patents. Not after they expire, but (multiple speakers)
我想我們已經解釋過,他們對那些專利仍然要負責。不是在到期之後,但(多位講者)
Roger George - VP, Legal Affairs and General Counsel
Roger George - VP, Legal Affairs and General Counsel
Sure. Once the patent expires it just means that the art disclosed in the patent can be freely practiced by anybody in the market. It doesn't make up for infringement during the life of the patent, for which anybody would be responsible for damaging.
當然。一旦專利到期,只代表該專利所揭露的技術內容,市場上任何人都可以自由實施。但這並不能彌補在專利存續期間的侵權行為;對於那段期間的侵權,任何人都要對損害賠償負責。
Steven Valiquette - Analyst
Steven Valiquette - Analyst
Okay. Got it. Maybe I'll just follow up off-line with some additional questions on that. Thanks.
好的。了解。我可能之後再私下追問一些相關問題。謝謝。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Let Marianne or -- and we can set up a call with Roger.
請讓 Marianne 或——,我們可以安排與 Roger 的電話會議。
Steven Valiquette - Analyst
Steven Valiquette - Analyst
Okay, thanks.
好的,謝謝。
Operator
Operator
Matt O'Brien, Piper Jaffray.
Matt O'Brien,Piper Jaffray。
Matt O'Brien - Analyst
Matt O'Brien - Analyst
So I got one here. EMEA growth continues to be very strong. How much of that growth is attributed to the expansion into non-core markets?
我這裡有一個問題。EMEA 的成長持續非常強勁。其中有多少成長可歸因於向非核心市場的擴張?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
You mean non-core markets to be other countries, Matt? What are you thinking there?
你指的非核心市場是其他國家嗎,Matt?你具體在想哪些?
Matt O'Brien - Analyst
Matt O'Brien - Analyst
Yes, correct. Yes.
是的,沒錯。是。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
I'd say it's minimal at first. When we look at India, moving into some different places. So I wouldn't look at that as material, but I might -- look at the Nordic countries in Europe, that we've done that three or four years ago, that starts to become important. So again, as we talk about moving into new markets, just think we have -- we laid out a lot of infrastructure, spend money, put salespeople in place. And then you start to see almost geometric growth in those areas. But that's not what I would say is the driver in any way right now of the kind of forecast we're giving into 2017 or what we saw in 2016.
我會說一開始影響很小。當我們看印度、以及進入一些不同的地區時。所以我不會把那視為具重大性,但我可能——會看歐洲的北歐國家,我們在三、四年前就做了,那開始變得重要。所以再說一次,當我們談到進入新市場時,只要想想我們——先鋪設了大量基礎建設、花錢、把業務人員配置到位。然後你就會開始在那些區域看到幾乎呈幾何級數的成長。但我不會說這在任何程度上是我們目前給到 2017 年的預測、或我們在 2016 年看到的表現之驅動因素。
Matt O'Brien - Analyst
Matt O'Brien - Analyst
Okay. And then also you guys pointed out low-volume docs in Q3. How did those guys perform in the quarter?
好的。另外你們也提到第三季的低量醫師。那些人在本季表現如何?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
They were good. Because we had the issue obviously in third quarter you are referring to. They came back pretty strong. You saw that GPs in the United States went from 3.1 to 3.2 from a utilization standpoint. That might sound small, but that's pretty big when you look at it across more than 150,000 GPs.
他們表現不錯。因為我們在第三季確實有你所指的那個問題。他們回升得相當強勁。你看到美國的全科牙醫(GPs)從使用率角度由 3.1 升到 3.2。這聽起來可能很小,但當你把它放在超過 150,000 名全科牙醫的規模來看,這其實相當大。
Matt O'Brien - Analyst
Matt O'Brien - Analyst
Okay, great. Thanks.
好的,很棒。謝謝。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Thanks, Matt. Operator, we'll take one more question, please.
謝謝你,Matt。接線員,請再讓我們接一個問題。
Operator
Operator
Jeffrey Matthews, Ram Partners.
Jeffrey Matthews,Ram Partners。
Jeffrey Matthews - Analyst
Jeffrey Matthews - Analyst
Two things. One, Joe, you mentioned in the script something about seeing improved evidence of clinical -- of efficacy. And I'm wondering where that came from and what impact it's having. Because back in the day, the pushback from orthos was all about a lack of clinical proof here, and so that sounds like a trend in the right direction.
兩件事。第一,Joe,你在講稿裡提到看到臨床——療效方面的證據有所改善。我想知道那是從哪裡來的,以及它帶來什麼影響。因為以前矯正科醫師的反對主要是缺乏臨床證據,所以這聽起來像是朝正確方向發展的趨勢。
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Jeff, I'd first say -- not to be a smartass or anything, but we've spent -- in the course of 20 years, $1 billion in trying to learn and accomplish significant, predictable orthodontic movement. And increasingly, as you see in our G series -- you know, from G3 all the way up to G7 we just announced -- we just improved that capability year in and year out. So, I think depending on when you take -- when you go back in history, many of the people in the orthodontic community, they have gone way off in their -- one, in their confidence in Invisalign.
Jeff,我先說——不是要耍聰明還是什麼,但我們在 20 年的過程中,投入了 10 億美元,試圖學習並達成顯著且可預測的矯正牙齒移動。而且你看到我們的 G 系列——你知道,從 G3 一路到我們剛宣布的 G7——我們年復一年地提升那項能力。所以,我想取決於你回溯到歷史上的哪個時間點,矯正社群中的許多人,他們對 Invisalign 的——第一,信心已經大幅提升。
And what's really critical to orthodontists in general is how you finish. And they have confidence that they can really finish. And more and more we hear that they have as much confidence in how Invisalign can finish as they do with wires and brackets. So, I hope I'm answering your question, but I (multiple speakers) --.
而對矯正科醫師一般而言,真正關鍵的是你如何收尾。他們有信心自己能把療程真正收尾完成。而我們越來越常聽到,他們對 Invisalign 的收尾能力的信心,已經不亞於對鋼絲與矯正器的信心。所以,我希望我有回答到你的問題,但我(多位講者)——。
Jeffrey Matthews - Analyst
Jeffrey Matthews - Analyst
No, that's right. No, I appreciate it. And don't worry, you are not being a smartass. I appreciate that. Second thing, you were early on, Joe, in this production shift, moving closer to end markets even before the election results made it sort of a headline issue. But given the comments that you made about how much you've invested in Juarez and high-tech it is, what are you learning about shifting to other countries, now that you are actually in the process of doing it in Asia and Europe? What have you learned? What surprised you, if anything?
不,沒錯。不,我很感謝。而且別擔心,你沒有在耍聰明。我很感謝。第二件事,你很早就開始推動這次生產轉移,把產能移到更接近終端市場的地方,甚至在選舉結果讓它成為頭條議題之前就開始了。但考量你提到你們在華雷斯投資了很多而且高度科技化,當你們現在實際在亞洲與歐洲推進時,對於轉移到其他國家你學到了什麼?你學到了什麼?有什麼讓你意外的地方嗎?
Joe Hogan - President and CEO
Joe Hogan - President and CEO
Honestly, Jeff, I've done this in other businesses I've been in, is to move production facilities from some location to others. And I'd say what we're learning here is what I've seen in other areas. One is, you never can just transfer production unit to unit. It's going to be different, and it has to reflect the culture of where you are moving to. So if we look at APAC, we'll probably look at different types of automation and different aspects of that plant. Because there's just a difference in what you'd have from a labor standpoint in Mexico to do that.
老實說,Jeff,我在我過去參與的其他事業也做過這件事,也就是把生產設施從某個地點移到其他地點。我會說我們在這裡學到的,跟我在其他地方看到的相同。第一,你永遠不可能只是把生產從一個單位直接轉移到另一個單位。它一定會不同,而且必須反映你要移入地點的文化。所以如果我們看亞太(APAC),我們可能會採用不同類型的自動化,以及那座工廠的不同面向。因為從勞動力的角度來看,墨西哥與那裡的情況就是不同。
I think we are learning that our infrastructure is really challenged in the sense of the IT piece and how you have to have much more flexibility to be able to handle these things when you get away from a unitary slide and you move to a broader area. What you also understand from our customers, you see the excitement from our customers, knowing that things like ClinCheck -- we're going to get closer to them in China because we can have many iterations, from Mandarin back to English, that goes between Costa Rica and China or different parts of APAC.
我想我們也學到,我們的基礎架構在 IT 這一塊確實面臨很大挑戰;當你不再是單一流程、而是擴展到更廣的區域時,你必須具備更高的彈性才能處理這些事情。另外,從客戶端你也能理解,你會看到客戶的興奮,因為像 ClinCheck 這類事情——我們會在中國更靠近他們,因為我們可以進行多次迭代,從中文到英文,在哥斯大黎加與中國或亞太不同地區之間往返。
Great excitement from our customer base to really improve that efficiency and to have more of a regional kind of a cultural aspect of the business as it moves closer [to them]. So those three things aren't a surprise to me, but what I really love is how much the customers embrace it and the regions embrace it. And we have flexibility in the sense of how we manufacture product and how we do things in that whole value chain that we talked about, between OA and clinical IT, and also on the fab piece. And we've used and disassemble and reassemble those teams around these areas to make it better for our customer base. And that's a great thing about this business.
我們的客戶群非常興奮,能真正提升效率,並且隨著業務更靠近[他們],帶來更多區域性、文化面的特質。所以這三件事對我來說不算意外,但我真正喜歡的是客戶與各區域對此的高度擁抱。而且我們在如何製造產品、以及在我們談到的整個價值鏈中如何運作方面具備彈性,介於 OA 與臨床 IT 之間,也包括製造(fab)這一塊。我們也把這些團隊拆解、再重組到各個區域周邊,讓它對我們的客戶群更好。這就是這門生意很棒的地方。
Jeffrey Matthews - Analyst
Jeffrey Matthews - Analyst
Great. Thanks so much.
很好。非常感謝。
Shirley Stacy - VP of Corporate Communications and IR
Shirley Stacy - VP of Corporate Communications and IR
Thanks, Jeff. Well, thank you everyone. This concludes our conference call. We appreciate you taking the time today. We'll look forward to seeing you at upcoming conferences, including Leerink and ROTH, as well as the Chicago Midwinter Dental Show at the end of February. If you have any follow-up questions, please contact Investor Relations.
謝謝你,Jeff。好,謝謝各位。本次電話會議到此結束。感謝各位今天撥冗參與。期待在接下來的會議上與各位見面,包括 Leerink 與 ROTH,以及二月底的芝加哥 Midwinter 牙科展。如有任何後續問題,請聯絡投資人關係部門。
Operator
Operator
This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time and have a wonderful rest of your day.
今天的會議到此結束。感謝各位的參與。您現在可以掛斷電話線,祝您今天剩餘時間愉快。